Dr. Gordon on Clinical Trials in Hodgkin Lymphoma

Leo I. Gordon, MD
Published: Thursday, Nov 30, 2017



Leo I. Gordon, MD, a professor of medicine at Feinberg School of Medicine, Northwestern University, discusses clinical trials in Hodgkin lymphoma.

Data suggests that the immune system and the use of checkpoint inhibitors may play an important role in Hodgkin lymphoma, says Gordon. These novel agents take the brakes off the immune system so it can attack the disease.

According to Gordon, there are trials comparing ABVD [adriamycin, bleomycin, vinblastine, dacarbazine] with other regimens, but ABVD remains the standard. However, the drug bleomycin causes pulmonary toxicity, especially in patients who are a little bit older with a smoking history.
 
SELECTED
LANGUAGE


Leo I. Gordon, MD, a professor of medicine at Feinberg School of Medicine, Northwestern University, discusses clinical trials in Hodgkin lymphoma.

Data suggests that the immune system and the use of checkpoint inhibitors may play an important role in Hodgkin lymphoma, says Gordon. These novel agents take the brakes off the immune system so it can attack the disease.

According to Gordon, there are trials comparing ABVD [adriamycin, bleomycin, vinblastine, dacarbazine] with other regimens, but ABVD remains the standard. However, the drug bleomycin causes pulmonary toxicity, especially in patients who are a little bit older with a smoking history.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x